Breaking News, Trials & Filings

OncoGenex Drug Gains Additional Fast Track Designation

OncoGenex Pharmaceuticals, Inc. received an additional Fast Track Designation from the FDA for OGX-011 (custirsen sodium) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

OncoGenex Pharmaceuticals, Inc. received an additional Fast Track Designation from the FDA for OGX-011 (custirsen sodium) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment. OGX-011 previously received Fast Track for second-line docetaxel treatment for progressive metastatic prostate cancer following docetaxel. Fast Track Designation is granted to products that may provide a significant improvement in the safety or effectiveness of the treatment for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters